Company Filing History:
Years Active: 2018
Title: The Innovative Contributions of Natalie DeJesus
Introduction
Natalie DeJesus is a prominent inventor based in Gaithersburg, MD (US). She has made significant strides in the field of biotechnology, particularly in the development of antibody formulations. Her work is characterized by a commitment to innovation and a focus on improving therapeutic options.
Latest Patents
Natalie holds a patent for a stable anti-IFNAR1 formulation. This invention relates to a stable, low viscosity antibody formulation that comprises a high concentration of anti-INFAR1 antibody. The formulation includes about 100 mg/mL to about 200 mg/mL of an antibody or fragment that specifically binds human interferon alpha 1 (INFAR1), along with other components such as lysine, surfactants, and formulation buffers. This patent represents a significant advancement in the field of antibody therapies.
Career Highlights
Natalie DeJesus is currently employed at AstraZeneca AB, where she continues to contribute to groundbreaking research and development. Her expertise in antibody formulation has positioned her as a valuable asset in her field. With a focus on stability and efficacy, her work is paving the way for new therapeutic solutions.
Collaborations
Throughout her career, Natalie has collaborated with notable colleagues, including Roberto Depaz and Jared Samuel Bee. These partnerships have fostered an environment of innovation and have led to the successful development of her patented formulations.
Conclusion
Natalie DeJesus exemplifies the spirit of innovation in biotechnology through her work on antibody formulations. Her contributions are not only advancing scientific knowledge but also enhancing therapeutic options for patients.